ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MAZE
ALVO (52) REPL (50) NVAX (49) VIR (40) ⌘ Pro Terminal →

Maze Therapeutics Inc. (MAZE) — RQD Stock Rating Cockpit

$31.48 -1.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.34

Maze Therapeutics Inc. (MAZE) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.75B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MAZE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MAZE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Maze Therapeutics Inc. (NASDAQ: MAZE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $31.48 (-1.41% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MAZE ranks #529 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MAZE compare to ALVO and REPL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MAZE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALVO (Alvotech) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.82B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MAZE?
▼

Per MAZE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001842295), Maze Therapeutics Inc. generated $400.1M in revenue (+138.9% YoY), -$131.1M in net income, and -$112.7M in free cash flow against $397.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $31.34 (-0.44%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (7)Whales (11)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$56 Bull$29 Base$22 Bear
📬 FREE MAZE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MAZE)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY MAZE SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (30% of score)

20D Institutional Volume Accumulation (±10.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$26.66+21.7% Next Q
Q2 (-2Q)
32
Grade E$32.45-2.3% Next Q
Q3 (-1Q)
34
Grade E$31.69-0.7% Next Q
Current
37
Grade D-$31.48-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MAZE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MAZE currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.58) and Max Pain ($33.05) forces dealer call-delta covering toward $56.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MAZE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MAZE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
61.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE30% OF RANGE
L: $22$31.48H: $54
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MAZE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -6.36% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

14/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like MAZE
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MAZE)

  • ✓Walkthrough of MAZE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MAZE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.90%📐 HORIZONTAL RANGE
2026-11-03O $31.93H $31.93L $31.48C $31.48VOL 327.1K
RES: $33.73SUP: $18.97SMA50: $27.58SMA200: $31.77
$37.56$33.33$29.10$24.87$20.64RES $33.73SUP $18.97$31.482026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MAZE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MAZE Butterfly Map → + Track MAZE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +138.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MAZE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MAZE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MAZE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MAZE)

Health Care Rank #529 of 1015 ⚔️ ALVO vs MAZE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MAZE vs. ALVO, REPL, NVAX, VIR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Maze Therapeutics Inc. (MAZE) ranks #529 by composite RQD confidence (37/100, grade D-) and #275 by equity capitalization ($1.75B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. ALVO currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with MAZE at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MAZE ACTIVE
Maze Therapeutics Inc.
D- 37/100 — — -35.0% -1.41% $1.75B Benchmark Subject
ALVO
Alvotech
D+ 52/100 — — — -4.91% $1.82B /alvo-vs-maze →
REPL
Replimune Group Inc.
D 50/100 — — -35.0% +1.26% $1.67B /repl-vs-maze →
NVAX
Novavax Inc.
D 49/100 3.9x 93.5% 85.0% -3.72% $1.66B /nvax-vs-maze →
VIR
Vir Biotechnology Inc.
D- 40/100 — 96.0% -35.0% -3.83% $1.93B /vir-vs-maze →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001842295 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maze Therapeutics Inc. (MAZE) reported GAAP revenue of $400.1M (+138.9% vs. FY2024 revenue of $167.5M ) , GAAP net income of -$131.1M, operating cash flow of -$111.9M, and free cash flow of -$112.7M (-250.7% YoY). On the balance sheet, MAZE closed FY2025 with $397.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $400.1M -$131.1M -$111.9M -$112.7M $397.1M —
FY2024 (FY) 2024-12-31 $167.5M $52.2M $76.0M $74.8M $240.5M —

3. MAZE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MAZE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Maze Therapeutics Inc. (NASDAQ: MAZE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $31.48 (-1.41% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MAZE ranks #529 in composite RQD confidence.

How does MAZE compare to ALVO and REPL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MAZE carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALVO (Alvotech) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.82B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MAZE?

Per MAZE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001842295), Maze Therapeutics Inc. generated $400.1M in revenue (+138.9% YoY), -$131.1M in net income, and -$112.7M in free cash flow against $397.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MAZE trading relative to its 50-day, 200-day, and 52-week technical levels?

MAZE last traded at $31.48 (-1.41% on volume of 327,149 shares), positioning the stock +14.14% above its 50-day simple moving average ($27.58) and -0.91% below its 200-day simple moving average ($31.77). Across its 52-week range of $21.95 to $53.65, MAZE sits at the 30.1% percentile with a 14-day RSI of 61.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.7% ($28.11 to $34.85).

Direct Sub-Reports: MAZE RQD Cockpit MAZE 12M Forecast MAZE Earnings & Move MAZE Dividends & DRIP MAZE Insiders & 13F MAZE Whale Options MAZE Profit Sankey MAZE News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MAZE — Maze Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Maze Therapeutics Inc. (MAZE) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $31.48 (-1.41% 1D, market capitalization $1.75B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.36%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Maze Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances)..8B. FY 2025 revenue is reported as —, while FY 2024 revenue was $167.5M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Maze Therapeutics Inc. (MAZE) reported $400.1M in annual revenue (up from $167.5M in FY2024, +138.9% YoY) and -$131.1M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($167.5M revenue, $52.2M net income) through FY2025, MAZE scaled operating cash flow to -$111.9M and free cash flow to -$112.7M, backed by $397.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.36% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $21.95 – $53.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), MAZE carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MAZE sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $400.1M and free cash flow of -$112.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MAZE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MAZE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Maze Therapeutics Inc. (MAZE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MAZE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MAZE Bull vs. Bear Conversation Board — What's Your Call at $31.48?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MAZE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MAZE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $40.61 (+29.0%)
📌 Pinned Debate

The stock has risen from a $21.95 low toward $31.93 amid a Canaccord Buy initiation on kidney drug potential.

The street is overcomplicating Maze Therapeutics Inc. (MAZE). The stock has risen from a $21.95 low toward $31.93 amid a Canaccord Buy initiation on kidney drug potential.. With an RQD score of 37/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $34.00.

SectorRotator 🐂 BULL

@DeepValue_CFA Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $31.48 and keeping dry powder in case we test $29.28.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $24.87 (-21.0%)
Spot @ $31.48

ROIC of -35% and an FY 2025 operating loss of -$142.9M, after FY 2024 operating income of $57.6M, show cash generation has reversed.

Sitting on the sidelines or leaning short MAZE above $31.48. ROIC of -35% and an FY 2025 operating loss of -$142.9M, after FY 2024 operating income of $57.6M, show cash generation has reversed.. Until Fundamental Cash Engine (7/20) and FCF yield (-6.36%) inflect higher, upside is capped near $53.65.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%